SOSV
SOSV is a global venture capital firm that supports early-stage startups through active, founder-first development programs. Its flagship initiatives HAX and IndieBio provide facilities, engineering resources, services, and laboratory equipment to accelerate product development and prepare companies for subsequent funding rounds. SOSV focuses on deep technology across health, environmental, and cross-border software sectors, aiming to solve human and planetary health challenges. In addition to providing capital, the firm emphasizes intensive programmatic support to help portfolio companies move quickly from seed toward growth, including customer acquisition and scale. The firm operates globally with a bias toward startups targeting rapid international expansion, especially in Asia, and tends to back a small cohort of high-potential companies to accelerate their progress and attract leading investors.
Top Sectors
https://crunchbase.com/organization/***
https://linkedin.com/company/***
https://signal.nfx.com/firms/***
Past deals in Genetics
Flore by Sun Genomics
Convertible Note in 2024
Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.
Synplexity
Seed Round in 2024
Synplexity is a biotechnology company located in New Castle, Delaware, specializing in mutational scanning and multiplexed gene synthesis through advanced artificial intelligence technology. The company operates a large-scale gene synthesis and proteomics discovery platform that utilizes microdroplets as microreactors. This innovative approach allows for the efficient creation of multiplex gene libraries, which have applications across various sectors, including therapeutics, biomanufacturing, agriculture, and climate systems. Synplexity aims to drive advancements in healthcare and other industries through its cutting-edge genetic technologies.
Gatehouse Bio
Convertible Note in 2024
Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.
Minutia
Seed Round in 2024
Minutia is a biotechnology company focused on developing innovative stem cell-derived transplants aimed at treating Type 1 Diabetes. The company specializes in creating insulin-producing cell transplants that incorporate proprietary nanosensors, allowing for real-time monitoring of transplant status. These immune-evasive cells are designed for subcutaneous implantation, addressing common challenges associated with transplant procedures. By advancing this technology, Minutia seeks to transform the clinical landscape for diabetes management and cell replacement therapies, ultimately working towards a functional cure for this condition.
Tinkeso Therapeutics
Seed Round in 2024
Tinkeso Therapeutics is a biotechnology company specializing in the development of innovative, off-the-shelf cell therapies for treating cancer and autoimmune diseases. The company focuses on creating allogeneic chimeric antigen receptor (CAR) engineered natural killer T (NKT) cell therapies, which use NKT cells to target and destroy cancer cells or modulate the immune response in autoimmune conditions. This approach aims to increase treatment accessibility and scalability by utilizing non-patient-specific cells.
OncoPrecision
Convertible Note in 2024
OncoPrecision develops a patient micro avatar platform that uses single-cell high-throughput biology and machine learning to provide comprehensive patient-derived phenotypic biomarkers. This enables oncologists to tailor cancer therapy across modalities, improving patient success through data-driven decisions based on patient-derived samples.
Helex
Convertible Note in 2024
Helex is a biotechnology company developing genomic medicines for kidney-related diseases. It leverages its own genomics data, bioinformatics, and an intelligent data-driven platform to design, verify, and deliver therapy-specific gRNAs, with a focus on non-viral targeted delivery and genome editing for renal indications. The company's platform uses data-driven deep-learning models and high-throughput sequencing data from CRISPR edits in human cell lines to generate reliable predictions and validate them in-house. By combining these capabilities, Helex aims to accelerate CRISPR-based drug research and the development of cell and gene therapies for kidney conditions, offering precise and scalable renal therapeutics.
CroBio
Seed Round in 2024
CroBio is an agricultural biotechnology company developing a sustainable solution for managing global agricultural drought. It uses genetically engineered root-associated bacteria to produce biomaterials that retain water in the soil, enhancing crop resilience and reducing irrigation requirements.
ClimateCrop
Seed Round in 2024
ClimateCrop develops gene editing and related plant technologies to enable crops to store more carbon and energy, with the goal of increasing yields in biomass and fruit. The approach also enhances crop resilience to extreme weather, supporting climate adaptation and more reliable production for agricultural companies. Founded in 2021 and based in Ness Ziona, the company focuses on leveraging plant energy capture to boost productivity.
DropGenie
Convertible Note in 2024
Founded in Montreal, Canada in 2018, DropGenie is a biotechnology company specializing in automated genetic engineering. It offers a platform that uses microfluidics technology to miniaturize and automate complex synthetic biology workflows, enabling scientists to make changes to genomes efficiently while reducing costs and improving standardization and reproducibility.
Reactosome
Seed Round in 2024
Reactosome is a biotechnology company that develops synthetic nuclei for gene therapy. Its core product, a synthetic nucleus, operates continuously within cells, mimicking the natural nucleus to affect multiple genes simultaneously. This approach aims to enhance the safety and longevity of gene expression, thereby enabling the development of treatments for complex diseases such as cancer and age-related disorders.
Flore by Sun Genomics
Series B in 2023
Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.
Gatehouse Bio
Convertible Note in 2023
Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.
CroBio
Convertible Note in 2023
CroBio is an agricultural biotechnology company developing a sustainable solution for managing global agricultural drought. It uses genetically engineered root-associated bacteria to produce biomaterials that retain water in the soil, enhancing crop resilience and reducing irrigation requirements.
TippingPoint Biosciences
Seed Round in 2023
TippingPoint Biosciences is developing therapeutics that target abnormal DNA packaging states in diseases such as cancer.
Diadem Biotherapeutics
Convertible Note in 2023
Diadem Biotherapeutics is a biotechnology company dedicated to developing bio-therapeutical materials through organic methods. The company specializes in the creation of exosomes, which are cell-free vesicles engineered to signal through validated targets. Diadem's therapeutic platform aims to treat a variety of chronic inflammatory conditions, autoimmune diseases, and cancers. By focusing on the genetic engineering, manufacturing, and purification of these exosomes, Diadem provides innovative solutions for clinicians to effectively address immunopathologies and improve patient outcomes.
Kresko RNAtech
Seed Round in 2023
Kresko RNAtech is a biotechnology company specializing in the development and production of nutraceuticals. It employs advanced techniques such as machine learning and bioinformatics to identify beneficial ribonucleic acids (RNAs) from natural sources, aiming to enhance human health and well-being.
DNALite Therapeutics
Convertible Note in 2023
DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative gene therapy treatments for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes advanced oral lipid nanoparticle technology to deliver mRNA and plasmid DNA directly to intestinal stem cells. This approach aims to address the root causes of gastrointestinal diseases, including Familial Adenomatous Polyposis (FAP), a hereditary condition that can lead to colorectal cancer and often necessitates invasive surgical interventions. DNALite's therapies seek to transform protein biologics into oral drugs, allowing for more effective and less invasive treatment options.
Renegade.bio
Series A in 2023
Renegade.bio is a biotechnology startup focused on the development and deployment of high-throughput diagnostics aimed at detecting novel infectious diseases. The company specializes in creating innovative diagnostics and assays that support drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). By leveraging these capabilities, Renegade.bio enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, and large events.
CroBio
Seed Round in 2023
CroBio is an agricultural biotechnology company developing a sustainable solution for managing global agricultural drought. It uses genetically engineered root-associated bacteria to produce biomaterials that retain water in the soil, enhancing crop resilience and reducing irrigation requirements.
Moirai Biodesign
Seed Round in 2023
Moirai Biodesign is a biotechnology company focused on developing RNA-based therapies and diagnostics for cancer. Founded in 2016, the company operates from Barcelona, Spain, and specializes in creating non-invasive tests for in-situ diagnosis of various cancers using patient blood samples. Additionally, it provides in-vivo diagnosis systems that assist in surgeries and facilitate patient monitoring. Moirai Biodesign's portfolio includes the discovery of RNA biomarkers, the design of plug-and-play bio devices, and a platform for delivering therapeutic drugs aimed at treating cancer. By advancing these technologies, the company aims to enhance early cancer detection and improve treatment outcomes.
Renegade.bio
Convertible Note in 2023
Renegade.bio is a biotechnology startup focused on the development and deployment of high-throughput diagnostics aimed at detecting novel infectious diseases. The company specializes in creating innovative diagnostics and assays that support drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). By leveraging these capabilities, Renegade.bio enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, and large events.
Cybele Microbiome
Convertible Note in 2022
Cybele Microbiome is a biotechnology company focused on enhancing skin health through precision control of the microbiome. The company utilizes a proprietary AI platform that integrates machine learning with advanced biotechnology and unique data sources to identify natural prebiotics. These prebiotics are designed to nourish the microbiome, leading to the development of customized skincare products. By employing genetic sequencing methods and sustainable nutrient sources, Cybele Microbiome aims to strengthen the skin's natural barrier and promote overall health and longevity. The innovative approach combines artificial intelligence with microbiome science to revolutionize skincare, enabling consumers to maintain the integrity of their skin through effective and conscientious skincare solutions.
Flore by Sun Genomics
Series B in 2022
Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.
Helex
Seed Round in 2022
Helex is a biotechnology company developing genomic medicines for kidney-related diseases. It leverages its own genomics data, bioinformatics, and an intelligent data-driven platform to design, verify, and deliver therapy-specific gRNAs, with a focus on non-viral targeted delivery and genome editing for renal indications. The company's platform uses data-driven deep-learning models and high-throughput sequencing data from CRISPR edits in human cell lines to generate reliable predictions and validate them in-house. By combining these capabilities, Helex aims to accelerate CRISPR-based drug research and the development of cell and gene therapies for kidney conditions, offering precise and scalable renal therapeutics.
Gatehouse Bio
Seed Round in 2022
Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.
Spindle Biotech
Seed Round in 2022
Spindle Biotech Inc., founded in 2017 and headquartered in Toronto, Canada, specializes in the development and commercialization of synthetic RNA technologies. The company focuses on a proprietary RNA polymerase that enhances large-scale mRNA vaccine production, reflecting the increasing relevance of synthetic RNA in biotechnological applications. Leveraging advances in mRNA technology, Spindle Biotech aims to facilitate high-throughput ribonucleoprotein (RNP)-based CRISPR and RNA screening. Utilizing advanced enzymes and microfluidic technology, it creates RNA arrays with high fidelity, which are vital for gene-editing and drug discovery initiatives. Through these innovations, Spindle Biotech seeks to support biotechnology companies in harnessing the transformative potential of synthetic RNA.
Flore by Sun Genomics
Convertible Note in 2022
Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.
Chronos DX
Seed Round in 2022
Chronos DX is a biotechnology research company based in London, Germany, specializing in drug development and in vitro diagnostics within the healthcare sector. The company is known for its innovative bioassay technology, which is designed for diagnostics, drug screening, and development. Chronos DX focuses on creating high-performance, low-cost, and scalable technology capable of detecting a variety of biomarkers, including cell-free DNA, micro proteins, exosomes, and metabolites. This technology provides medical professionals with a platform for in-line and in vivo monitoring of biomarkers, enhancing the capabilities of diagnostics and drug development in medical practice.
Moirai Biodesign
Convertible Note in 2022
Moirai Biodesign is a biotechnology company focused on developing RNA-based therapies and diagnostics for cancer. Founded in 2016, the company operates from Barcelona, Spain, and specializes in creating non-invasive tests for in-situ diagnosis of various cancers using patient blood samples. Additionally, it provides in-vivo diagnosis systems that assist in surgeries and facilitate patient monitoring. Moirai Biodesign's portfolio includes the discovery of RNA biomarkers, the design of plug-and-play bio devices, and a platform for delivering therapeutic drugs aimed at treating cancer. By advancing these technologies, the company aims to enhance early cancer detection and improve treatment outcomes.
Briefcase Biotec
Convertible Note in 2022
Briefcase Biotec develops KiloBaser, a Nespresso machine of DNA synthesis - enabling cutting edge research without detours.
KiloBaser is a device for printing short synthetic DNA sequences. It enables individual scientists to easily produce the DNA they need on their desktops, while speeding up production of the basics for all genetic engineering and synthetic biology research and development.
Headquartered in Graz, Steiermark, KiloBaser was founded in 2013 by Martin Jost and Alexander Murer.
Gatehouse Bio
Convertible Note in 2022
Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.
ClimateCrop
Seed Round in 2022
ClimateCrop develops gene editing and related plant technologies to enable crops to store more carbon and energy, with the goal of increasing yields in biomass and fruit. The approach also enhances crop resilience to extreme weather, supporting climate adaptation and more reliable production for agricultural companies. Founded in 2021 and based in Ness Ziona, the company focuses on leveraging plant energy capture to boost productivity.
DNALite Therapeutics
Venture Round in 2022
DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative gene therapy treatments for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes advanced oral lipid nanoparticle technology to deliver mRNA and plasmid DNA directly to intestinal stem cells. This approach aims to address the root causes of gastrointestinal diseases, including Familial Adenomatous Polyposis (FAP), a hereditary condition that can lead to colorectal cancer and often necessitates invasive surgical interventions. DNALite's therapies seek to transform protein biologics into oral drugs, allowing for more effective and less invasive treatment options.
Innatrix
Seed Round in 2022
Innatrix is an agricultural biotechnology company focused on developing innovative biological and chemical solutions to address crop diseases, pests, and weeds that are otherwise difficult to manage. Utilizing patented protein evolution technology, the company has established a peptide and RNA interference delivery platform that offers eco-friendly alternatives for crop protection. Innatrix's proprietary automated platform facilitates protein engineering through continuous laboratory evolution and advanced techniques such as phage display. This technology empowers researchers with enhanced control, reporting, recording, simulation, and remote access capabilities, thereby advancing the field of agricultural biotechnology and promoting sustainable farming practices.
Innatrix
Convertible Note in 2022
Innatrix is an agricultural biotechnology company focused on developing innovative biological and chemical solutions to address crop diseases, pests, and weeds that are otherwise difficult to manage. Utilizing patented protein evolution technology, the company has established a peptide and RNA interference delivery platform that offers eco-friendly alternatives for crop protection. Innatrix's proprietary automated platform facilitates protein engineering through continuous laboratory evolution and advanced techniques such as phage display. This technology empowers researchers with enhanced control, reporting, recording, simulation, and remote access capabilities, thereby advancing the field of agricultural biotechnology and promoting sustainable farming practices.
ArgenTAG
Pre Seed Round in 2022
ArgenTAG is a biotechnology company specializing in genomic sequencing. It offers a proprietary technology designed to reduce the cost of long-read sequencing applications.
ArgenTAG
Convertible Note in 2022
ArgenTAG is a biotechnology company specializing in genomic sequencing. It offers a proprietary technology designed to reduce the cost of long-read sequencing applications.
Inso Biosciences
Convertible Note in 2022
Inso Biosciences is an early-stage biotechnology company that develops microfluidic hardware platforms for genomic sample handling. The company's patented microfluidic technology enables high-efficiency processing of cellular material and the separation and isolation of cellular components, supporting genomic analysis and DNA sequencing workflows. Its platform aims to improve long-read DNA extraction, multiomic sample processing, and pathogen surveillance, enabling healthcare and biotech organizations to perform biological sample preparation with greater efficiency and accuracy.
veMico
Seed Round in 2021
VemiCo is a biotechnology company focused on extending healthy living by addressing the aging process. The company leverages artificial intelligence and synthetic biology to discover and advance promising molecules derived from gut microbial DNA. By harnessing the potential of microbiomes, VemiCo aims to enhance gut health and overall well-being, offering innovative solutions for medical professionals in the health sector.
Circularis Biotechnologies
Convertible Note in 2021
Circularis Biotechnologies, Inc. is a biotechnology company founded in 2014 and headquartered in Oakland, California. The company specializes in developing innovative methods to regulate gene expression, which enhances the production yields of biotherapeutics. Circularis offers a range of products, including RACRE Variant Libraries, hCMV Variant Library, Protein expression with CMV promoters, and T7 Variant Library. In addition, it provides various services such as RACRE Enhancement, RACRE Discovery, RACRE Technology Access Program, and Ribozyme Analysis of Cis-Regulatory Elements. Through its advanced technologies and services, Circularis aims to improve the efficiency and effectiveness of biotherapeutic production.
ClimateCrop
Convertible Note in 2021
ClimateCrop develops gene editing and related plant technologies to enable crops to store more carbon and energy, with the goal of increasing yields in biomass and fruit. The approach also enhances crop resilience to extreme weather, supporting climate adaptation and more reliable production for agricultural companies. Founded in 2021 and based in Ness Ziona, the company focuses on leveraging plant energy capture to boost productivity.
ClimateCrop
Seed Round in 2021
ClimateCrop develops gene editing and related plant technologies to enable crops to store more carbon and energy, with the goal of increasing yields in biomass and fruit. The approach also enhances crop resilience to extreme weather, supporting climate adaptation and more reliable production for agricultural companies. Founded in 2021 and based in Ness Ziona, the company focuses on leveraging plant energy capture to boost productivity.
Gatehouse Bio
Seed Round in 2021
Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.
SEQUENTIAL
Seed Round in 2021
Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.
DropGenie
Seed Round in 2021
Founded in Montreal, Canada in 2018, DropGenie is a biotechnology company specializing in automated genetic engineering. It offers a platform that uses microfluidics technology to miniaturize and automate complex synthetic biology workflows, enabling scientists to make changes to genomes efficiently while reducing costs and improving standardization and reproducibility.
Catalog
Series B in 2021
Catalog Technologies Inc. specializes in a DNA-based platform that revolutionizes digital data storage and computation. Founded in 2016 and headquartered in Boston, Massachusetts, the company provides a method for encoding digital information into DNA, making it a viable and cost-effective solution for long-term data archiving. By leveraging advanced synthetic biology technologies, Catalog aims to transform how information is stored, allowing customers to utilize DNA molecules as a primary medium for digital records. This innovative approach positions Catalog at the forefront of next-generation data storage solutions.
Indee Labs
Convertible Note in 2021
Indee Labs develops hardware and platform technologies for gene delivery to immune cells, with the aim of enabling the rapid development and scalable manufacture of gene-modified cell therapies, including CAR-T cells. The company focuses on non-viral delivery methods to introduce small molecules, nucleic acids, proteins, and gene-editing complexes into immune cells, supporting biopharmaceutical research and manufacturing while maintaining high cell viability and function. Its technology has progressed with collaboration from national facilities and through participation in biotech incubators and accelerators. Indee Labs maintains an international footprint, with an office in Sydney and lab space in Berkeley, reflecting its cross-regional development and manufacturing focus.
SEQUENTIAL
Convertible Note in 2021
Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.
Helex
Convertible Note in 2021
Helex is a biotechnology company developing genomic medicines for kidney-related diseases. It leverages its own genomics data, bioinformatics, and an intelligent data-driven platform to design, verify, and deliver therapy-specific gRNAs, with a focus on non-viral targeted delivery and genome editing for renal indications. The company's platform uses data-driven deep-learning models and high-throughput sequencing data from CRISPR edits in human cell lines to generate reliable predictions and validate them in-house. By combining these capabilities, Helex aims to accelerate CRISPR-based drug research and the development of cell and gene therapies for kidney conditions, offering precise and scalable renal therapeutics.
Helex
Seed Round in 2021
Helex is a biotechnology company developing genomic medicines for kidney-related diseases. It leverages its own genomics data, bioinformatics, and an intelligent data-driven platform to design, verify, and deliver therapy-specific gRNAs, with a focus on non-viral targeted delivery and genome editing for renal indications. The company's platform uses data-driven deep-learning models and high-throughput sequencing data from CRISPR edits in human cell lines to generate reliable predictions and validate them in-house. By combining these capabilities, Helex aims to accelerate CRISPR-based drug research and the development of cell and gene therapies for kidney conditions, offering precise and scalable renal therapeutics.
SEQUENTIAL
Convertible Note in 2021
Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.
Diadem Biotherapeutics
Convertible Note in 2021
Diadem Biotherapeutics is a biotechnology company dedicated to developing bio-therapeutical materials through organic methods. The company specializes in the creation of exosomes, which are cell-free vesicles engineered to signal through validated targets. Diadem's therapeutic platform aims to treat a variety of chronic inflammatory conditions, autoimmune diseases, and cancers. By focusing on the genetic engineering, manufacturing, and purification of these exosomes, Diadem provides innovative solutions for clinicians to effectively address immunopathologies and improve patient outcomes.
CyGenica
Seed Round in 2021
CyGenica develops non-viral, non-toxic platforms for delivering drugs, gene editing components, and antibiotics into cells. Its technology enables targeted delivery to specific cellular locations, enhancing the efficacy of pharmaceuticals.
DNALite Therapeutics
Convertible Note in 2021
DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative gene therapy treatments for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes advanced oral lipid nanoparticle technology to deliver mRNA and plasmid DNA directly to intestinal stem cells. This approach aims to address the root causes of gastrointestinal diseases, including Familial Adenomatous Polyposis (FAP), a hereditary condition that can lead to colorectal cancer and often necessitates invasive surgical interventions. DNALite's therapies seek to transform protein biologics into oral drugs, allowing for more effective and less invasive treatment options.
Basin Genomics
Convertible Note in 2021
Basin Genomics is combining scientific backgrounds in genomics and oncology with startup expertise to translate genetic discoveries into advances in personalized clinical care as it strives to develop technology that will decrease the rates of cervical cancer globally.
Basin Genomics
Seed Round in 2021
Basin Genomics is combining scientific backgrounds in genomics and oncology with startup expertise to translate genetic discoveries into advances in personalized clinical care as it strives to develop technology that will decrease the rates of cervical cancer globally.
SEQUENTIAL
Pre Seed Round in 2021
Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.
Gatehouse Bio
Funding Round in 2021
Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.
Gatehouse Bio
Seed Round in 2020
Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.
Biomage
Seed Round in 2020
Biomage is a company dedicated to advancing life sciences through innovative single-cell analysis. It offers a platform that enables researchers to analyze vast single-cell sequencing data efficiently, transforming complex biological data into actionable insights. This capability supports both academic and industrial scientists in enhancing drug target discovery while reducing costs. The Biomage Single Cell Platform allows users to manage their single-cell data analysis with ease, providing deep biological insights in a streamlined manner. By applying advanced computational methods, Biomage is at the forefront of facilitating groundbreaking research across various biological disciplines.
OncoPrecision
Pre Seed Round in 2020
OncoPrecision develops a patient micro avatar platform that uses single-cell high-throughput biology and machine learning to provide comprehensive patient-derived phenotypic biomarkers. This enables oncologists to tailor cancer therapy across modalities, improving patient success through data-driven decisions based on patient-derived samples.
Magellan Life Sciences
Seed Round in 2020
Magellan Life Sciences Ltd. is a synthetic biology company based in London, United Kingdom, established in 2018. The company specializes in developing proprietary protein engineering and expression platforms, focusing on plant-inspired proteins for commercial applications in the food and beverage industries. One of its notable products is brazzein, a protein sweetener designed to provide a non-caloric alternative for consumers, addressing concerns related to sugar content and associated health issues. Additionally, Magellan Life Sciences is advancing its XSeed platform, which further enhances its capabilities in creating novel protein-based molecules tailored for the food, health, and nutrition sectors.
Moirai Biodesign
Convertible Note in 2020
Moirai Biodesign is a biotechnology company focused on developing RNA-based therapies and diagnostics for cancer. Founded in 2016, the company operates from Barcelona, Spain, and specializes in creating non-invasive tests for in-situ diagnosis of various cancers using patient blood samples. Additionally, it provides in-vivo diagnosis systems that assist in surgeries and facilitate patient monitoring. Moirai Biodesign's portfolio includes the discovery of RNA biomarkers, the design of plug-and-play bio devices, and a platform for delivering therapeutic drugs aimed at treating cancer. By advancing these technologies, the company aims to enhance early cancer detection and improve treatment outcomes.
Renegade.bio
Convertible Note in 2020
Renegade.bio is a biotechnology startup focused on the development and deployment of high-throughput diagnostics aimed at detecting novel infectious diseases. The company specializes in creating innovative diagnostics and assays that support drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). By leveraging these capabilities, Renegade.bio enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, and large events.
Cybele Microbiome
Seed Round in 2020
Cybele Microbiome is a biotechnology company focused on enhancing skin health through precision control of the microbiome. The company utilizes a proprietary AI platform that integrates machine learning with advanced biotechnology and unique data sources to identify natural prebiotics. These prebiotics are designed to nourish the microbiome, leading to the development of customized skincare products. By employing genetic sequencing methods and sustainable nutrient sources, Cybele Microbiome aims to strengthen the skin's natural barrier and promote overall health and longevity. The innovative approach combines artificial intelligence with microbiome science to revolutionize skincare, enabling consumers to maintain the integrity of their skin through effective and conscientious skincare solutions.
Cybele Microbiome
Convertible Note in 2020
Cybele Microbiome is a biotechnology company focused on enhancing skin health through precision control of the microbiome. The company utilizes a proprietary AI platform that integrates machine learning with advanced biotechnology and unique data sources to identify natural prebiotics. These prebiotics are designed to nourish the microbiome, leading to the development of customized skincare products. By employing genetic sequencing methods and sustainable nutrient sources, Cybele Microbiome aims to strengthen the skin's natural barrier and promote overall health and longevity. The innovative approach combines artificial intelligence with microbiome science to revolutionize skincare, enabling consumers to maintain the integrity of their skin through effective and conscientious skincare solutions.
Flore by Sun Genomics
Series A in 2020
Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.
Renegade.bio
Convertible Note in 2020
Renegade.bio is a biotechnology startup focused on the development and deployment of high-throughput diagnostics aimed at detecting novel infectious diseases. The company specializes in creating innovative diagnostics and assays that support drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). By leveraging these capabilities, Renegade.bio enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, and large events.
DropGenie
Convertible Note in 2020
Founded in Montreal, Canada in 2018, DropGenie is a biotechnology company specializing in automated genetic engineering. It offers a platform that uses microfluidics technology to miniaturize and automate complex synthetic biology workflows, enabling scientists to make changes to genomes efficiently while reducing costs and improving standardization and reproducibility.
Biomage
Pre Seed Round in 2020
Biomage is a company dedicated to advancing life sciences through innovative single-cell analysis. It offers a platform that enables researchers to analyze vast single-cell sequencing data efficiently, transforming complex biological data into actionable insights. This capability supports both academic and industrial scientists in enhancing drug target discovery while reducing costs. The Biomage Single Cell Platform allows users to manage their single-cell data analysis with ease, providing deep biological insights in a streamlined manner. By applying advanced computational methods, Biomage is at the forefront of facilitating groundbreaking research across various biological disciplines.
Renegade.bio
Seed Round in 2020
Renegade.bio is a biotechnology startup focused on the development and deployment of high-throughput diagnostics aimed at detecting novel infectious diseases. The company specializes in creating innovative diagnostics and assays that support drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). By leveraging these capabilities, Renegade.bio enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, and large events.
Ivy Natal
Seed Round in 2020
Ivy Natal is a biotechnology company focused on addressing infertility through innovative reproductive solutions. The company has developed a skin biopsy technology that enables the creation of human egg cells from skin samples. This process activates the existing DNA within skin cells to transform them into healthy egg cells, offering a novel alternative to traditional in vitro methods for producing eggs and sperm. By circumventing the challenges associated with conventional reproductive techniques, Ivy Natal aims to provide couples, including those in same-sex relationships, with the opportunity to have genetically related children.
Circularis Biotechnologies
Seed Round in 2020
Circularis Biotechnologies, Inc. is a biotechnology company founded in 2014 and headquartered in Oakland, California. The company specializes in developing innovative methods to regulate gene expression, which enhances the production yields of biotherapeutics. Circularis offers a range of products, including RACRE Variant Libraries, hCMV Variant Library, Protein expression with CMV promoters, and T7 Variant Library. In addition, it provides various services such as RACRE Enhancement, RACRE Discovery, RACRE Technology Access Program, and Ribozyme Analysis of Cis-Regulatory Elements. Through its advanced technologies and services, Circularis aims to improve the efficiency and effectiveness of biotherapeutic production.
Briefcase Biotec
Convertible Note in 2020
Briefcase Biotec develops KiloBaser, a Nespresso machine of DNA synthesis - enabling cutting edge research without detours.
KiloBaser is a device for printing short synthetic DNA sequences. It enables individual scientists to easily produce the DNA they need on their desktops, while speeding up production of the basics for all genetic engineering and synthetic biology research and development.
Headquartered in Graz, Steiermark, KiloBaser was founded in 2013 by Martin Jost and Alexander Murer.
Catalog
Series A in 2020
Catalog Technologies Inc. specializes in a DNA-based platform that revolutionizes digital data storage and computation. Founded in 2016 and headquartered in Boston, Massachusetts, the company provides a method for encoding digital information into DNA, making it a viable and cost-effective solution for long-term data archiving. By leveraging advanced synthetic biology technologies, Catalog aims to transform how information is stored, allowing customers to utilize DNA molecules as a primary medium for digital records. This innovative approach positions Catalog at the forefront of next-generation data storage solutions.
Renegade.bio
Debt Financing in 2020
Renegade.bio is a biotechnology startup focused on the development and deployment of high-throughput diagnostics aimed at detecting novel infectious diseases. The company specializes in creating innovative diagnostics and assays that support drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). By leveraging these capabilities, Renegade.bio enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, and large events.
CASPR Biotech
Convertible Note in 2020
CASPR Biotech is a San Francisco-based company established in 2018 that specializes in the development of a CRISPR-based platform for diagnosing antimicrobial resistances (AMR) and infectious diseases. The company focuses on creating portable diagnostic kits that utilize proprietary CRISPR Cas enzymes to detect specific DNA and RNA sequences, as well as signature amino acid sequences associated with infectious diseases and genetic mutations. These kits are designed to provide clinicians with a simple, fast, and affordable solution for molecular detection, enhancing the efficiency of disease identification in clinical and hospital settings.
Moirai Biodesign
Seed Round in 2019
Moirai Biodesign is a biotechnology company focused on developing RNA-based therapies and diagnostics for cancer. Founded in 2016, the company operates from Barcelona, Spain, and specializes in creating non-invasive tests for in-situ diagnosis of various cancers using patient blood samples. Additionally, it provides in-vivo diagnosis systems that assist in surgeries and facilitate patient monitoring. Moirai Biodesign's portfolio includes the discovery of RNA biomarkers, the design of plug-and-play bio devices, and a platform for delivering therapeutic drugs aimed at treating cancer. By advancing these technologies, the company aims to enhance early cancer detection and improve treatment outcomes.
Farma Genetix
Seed Round in 2019
Farma Genetix is a Boston-based company that specializes in manufacturing genetically tailored natural supplements and personalized diet plans aimed at addressing chronic health conditions. By collaborating with researchers from Harvard Medical School's Genomics department, Farma Genetix develops nutritional products designed to support cardiovascular health, including the maintenance of healthy blood pressure and cholesterol levels. The company emphasizes the importance of a customized dietary approach to promote overall well-being and reinforce a healthy lifestyle.
Flore by Sun Genomics
Convertible Note in 2019
Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.
veMico
Seed Round in 2019
VemiCo is a biotechnology company focused on extending healthy living by addressing the aging process. The company leverages artificial intelligence and synthetic biology to discover and advance promising molecules derived from gut microbial DNA. By harnessing the potential of microbiomes, VemiCo aims to enhance gut health and overall well-being, offering innovative solutions for medical professionals in the health sector.
Ravata Solutions
Convertible Note in 2019
Ravata Solutions develops a medical device platform for gene delivery used to create custom transgenic animal models and support production-scale embryo engineering. Founded in 2016 and based in Davis, California, the company targets pre-clinical research by enabling faster creation of transgenic organisms and improving embryo viability for disease modeling and fertility applications. The technology is designed to streamline model development for drug efficacy studies and medical genetics research, helping researchers accelerate timelines while enhancing the reliability of embryo production and genetic modification processes.
CorNatural
Seed Round in 2019
CorNatural develops bio-based sustainable products by upcycling waste streams into valuable items. They employ innovative synthetic biology and genetic engineering methods.
Diadem Biotherapeutics
Seed Round in 2019
Diadem Biotherapeutics is a biotechnology company dedicated to developing bio-therapeutical materials through organic methods. The company specializes in the creation of exosomes, which are cell-free vesicles engineered to signal through validated targets. Diadem's therapeutic platform aims to treat a variety of chronic inflammatory conditions, autoimmune diseases, and cancers. By focusing on the genetic engineering, manufacturing, and purification of these exosomes, Diadem provides innovative solutions for clinicians to effectively address immunopathologies and improve patient outcomes.
Dahlia Biosciences
Convertible Note in 2019
Founded in 2011, Dahlia Biosciences is a biotechnology company specializing in single-cell RNA analysis tools for research and diagnostic applications. It uses CRISPR-Cas9 technology to detect multiple DNA and RNA biomarkers directly in cells and tissues.
DNALite Therapeutics
Seed Round in 2019
DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative gene therapy treatments for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes advanced oral lipid nanoparticle technology to deliver mRNA and plasmid DNA directly to intestinal stem cells. This approach aims to address the root causes of gastrointestinal diseases, including Familial Adenomatous Polyposis (FAP), a hereditary condition that can lead to colorectal cancer and often necessitates invasive surgical interventions. DNALite's therapies seek to transform protein biologics into oral drugs, allowing for more effective and less invasive treatment options.
DropGenie
Seed Round in 2019
Founded in Montreal, Canada in 2018, DropGenie is a biotechnology company specializing in automated genetic engineering. It offers a platform that uses microfluidics technology to miniaturize and automate complex synthetic biology workflows, enabling scientists to make changes to genomes efficiently while reducing costs and improving standardization and reproducibility.
Beeline Therapeutics
Seed Round in 2019
Beeline Therapeutics is an early-stage preclinical cell therapy company focused on developing next-generation immune cell therapies for immune-mediated diseases, where the body's immune cells mistakenly attack healthy tissue. The company specializes in genetically engineering a patient's own immune cells, specifically Regulatory T cells, to secrete therapeutic proteins in vivo and promote tolerance. By enhancing the function of these re-engineered Tregs, Beeline aims to produce optimal quantities of immunomodulatory cytokines, antibodies, and other therapeutic proteins. Additionally, the company is working on improving antigen specificity through targeting receptors, which aids in better localization of these engineered cells within the body, ultimately contributing to the advancement of innovative treatments for immune-mediated human diseases.
Spindle Biotech
Seed Round in 2019
Spindle Biotech Inc., founded in 2017 and headquartered in Toronto, Canada, specializes in the development and commercialization of synthetic RNA technologies. The company focuses on a proprietary RNA polymerase that enhances large-scale mRNA vaccine production, reflecting the increasing relevance of synthetic RNA in biotechnological applications. Leveraging advances in mRNA technology, Spindle Biotech aims to facilitate high-throughput ribonucleoprotein (RNP)-based CRISPR and RNA screening. Utilizing advanced enzymes and microfluidic technology, it creates RNA arrays with high fidelity, which are vital for gene-editing and drug discovery initiatives. Through these innovations, Spindle Biotech seeks to support biotechnology companies in harnessing the transformative potential of synthetic RNA.
CASPR Biotech
Pre Seed Round in 2019
CASPR Biotech is a San Francisco-based company established in 2018 that specializes in the development of a CRISPR-based platform for diagnosing antimicrobial resistances (AMR) and infectious diseases. The company focuses on creating portable diagnostic kits that utilize proprietary CRISPR Cas enzymes to detect specific DNA and RNA sequences, as well as signature amino acid sequences associated with infectious diseases and genetic mutations. These kits are designed to provide clinicians with a simple, fast, and affordable solution for molecular detection, enhancing the efficiency of disease identification in clinical and hospital settings.
Serenity Bioworks
Convertible Note in 2019
Serenity Bioworks is a biotechnology company focused on developing innovative antibody mimetics for targeted protein degradation. The company employs advanced display techniques alongside computational methods to optimize the discovery process of these therapeutics. Additionally, Serenity Bioworks is engaged in creating gene therapies aimed at addressing underserved areas in healthcare, such as hemophilia, inherited retinal diseases, and neurodegenerative conditions. Their goal is to enhance the long-term efficacy and safety profiles of gene therapy treatments, ultimately improving patient outcomes with safer and more durable solutions.
Helixworks Technologies Limited
Seed Round in 2019
Helixworks Technologies Limited is a Cork, Ireland-based biotechnology company focused on DNA data storage and programmable biology. It develops a molecular storage system that stores digital information in DNA using an open architecture. The company advances enzymatic DNA synthesis methods and provides an end-to-end platform for DNA data storage, equipping developers with tools and services for molecular tagging, digital preservation and multiplexed next-generation sequencing applications, including barcoding kits for NGS workflows. By treating biology as an engineering discipline, Helixworks aims to enable the development of living machines and support healthcare data management and other advanced applications.
Flore by Sun Genomics
Venture Round in 2019
Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.
Chronomics
Seed Round in 2019
Chronomics Ltd is a tech-bio company headquartered in Norwich, United Kingdom, that specializes in developing testing kits and an artificial intelligence platform for DNA methylation analysis. Founded in 2017, the company provides insights into biological age, smoke exposure, and metabolic state, as well as health risks, eye color, and hereditary intolerances. Chronomics aims to make biological information accessible and actionable, simplifying the use of biomarkers across various sectors, including telehealth, travel, and personal care. By partnering with major organizations, Chronomics seeks to enhance how individuals diagnose and personalize their health and wellness decisions, contributing to a broader bio-revolution that aims to transform everyday life through scientific innovation.
Briefcase Biotec
Convertible Note in 2018
Briefcase Biotec develops KiloBaser, a Nespresso machine of DNA synthesis - enabling cutting edge research without detours.
KiloBaser is a device for printing short synthetic DNA sequences. It enables individual scientists to easily produce the DNA they need on their desktops, while speeding up production of the basics for all genetic engineering and synthetic biology research and development.
Headquartered in Graz, Steiermark, KiloBaser was founded in 2013 by Martin Jost and Alexander Murer.
Dahlia Biosciences
Convertible Note in 2018
Founded in 2011, Dahlia Biosciences is a biotechnology company specializing in single-cell RNA analysis tools for research and diagnostic applications. It uses CRISPR-Cas9 technology to detect multiple DNA and RNA biomarkers directly in cells and tissues.
DNALite Therapeutics
Seed Round in 2018
DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative gene therapy treatments for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes advanced oral lipid nanoparticle technology to deliver mRNA and plasmid DNA directly to intestinal stem cells. This approach aims to address the root causes of gastrointestinal diseases, including Familial Adenomatous Polyposis (FAP), a hereditary condition that can lead to colorectal cancer and often necessitates invasive surgical interventions. DNALite's therapies seek to transform protein biologics into oral drugs, allowing for more effective and less invasive treatment options.
Osiris Bio
Seed Round in 2018
Osiris Bio
Moirai Biodesign
Seed Round in 2018
Moirai Biodesign is a biotechnology company focused on developing RNA-based therapies and diagnostics for cancer. Founded in 2016, the company operates from Barcelona, Spain, and specializes in creating non-invasive tests for in-situ diagnosis of various cancers using patient blood samples. Additionally, it provides in-vivo diagnosis systems that assist in surgeries and facilitate patient monitoring. Moirai Biodesign's portfolio includes the discovery of RNA biomarkers, the design of plug-and-play bio devices, and a platform for delivering therapeutic drugs aimed at treating cancer. By advancing these technologies, the company aims to enhance early cancer detection and improve treatment outcomes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.